Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccin...(t of viralinfections and cancer with a f...),Health

This press release contains statements which may constitute forward- looking information under applicable Canadian securities legislation or forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking statements or information may include financial and other projections as well as statements regarding the company's future plans, objectives, performance, revenues, growth, profits, operating expenses or the company's underlying assumptions. The words "may", "would", "could", "will", "likely", "expect," "anticipate," "intend", "plan", "forecast", "project", "estimate" and "believe" or other similar words and phrases may identify forward-looking statements or information. Persons reading this press release are cautioned that such statements or information are only predictions, and that the company's actual future results or performance may be materially different.

Forward-looking statements or information in this press release include, but are not limited to, statements or information concerning: Poly-ICR's potential for use in both therapeutic and prophylactic vaccines; our plans to incorporate Poly-ICR into future internal product candidates; the development of Poly-ICR for topical application for the treatment of GW and actinic keratosis; our belief that Poly-ICR will evolve into a revenue generating opportunity for Nventa in the near future; Poly-ICR's ability to induce both cytotoxic and antibody immune responses; and our expectation that our manufacturing process can be used to produce cGMP Poly-ICR.

Such forward-looking statements or information involve k
'/>"/>